Third Harmonic Bio Announces Second Quarter 2023 Financial Results (GlobeNewswire) - Aug 10, 2023 - P1b | N=5 | NCT05510843 | Sponsor: Third Harmonic Bio | "Third Harmonic Bio, Inc...today announced financial results for the second quarter ended June 30, 2023...the company announced its next-generation product candidate, THB335, and disclosed topline results of the Phase 1b clinical trial of THB001 for the treatment of chronic inducible urticaria, which was discontinued in December 2022 due to observed liver transaminitis in two of five patients enrolled. The results demonstrated evidence of clinical benefit in four of the five patients, achieving partial or complete responses despite early termination of the trial...The company plans to file a U.S. IND and initiate clinical trials of THB335 in the first half of 2024....Cash and cash equivalents totaled $278.1 million as of June 30, 2023."
Commercial • IND • P1 data • Dermatology • Immunology • Urticaria
|